Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BAY86-9596 · BAY86, BAY-86-9596 F-18

Radiopharmaceutical · developed by Lantheus Biosciences

Phase 1 Most advanced trial (none active)
LNTH Developer
1 Registered trials

What is BAY86-9596?

BAY86-9596 is an F-18 labeled radiopharmaceutical given as a single intravenous bolus for whole body PET/CT imaging.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BAY86, BAY-86-9596 F-18
Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Lantheus Biosciences Ltd. (LNTH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
58HVN5SR99

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01089998 Phase 1 Diagnostic Imaging Completed LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diagnostic Imaging

More from Lantheus Biosciences

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind BAY86-9596

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.